Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
- Citation:
- Eur J Cancer vol 117 91-8
- Year:
- 2019
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 8
- Parents:
- 2679
- Children:
- None
- Pharmas:
- Genentech, Roche
- Grants:
- U10CA180821, U10CA180882, P30 CA008748, U10CA180838, U10CA180867
- Corr. Author:
- Authors:
- M Martín S Loibl T Hyslop J De la Haba-Rodríguez B Aktas C T Cirrincione K Mehta W T Barry S Morales L A Carey J A Garcia-Saenz A Partridge N Martinez-Jañez O Hahn E Winer A Guerrero-Zotano C Hudis M Casas C Rodriguez-Martin J Furlanetto E Carrasco M N Dickler
- Networks:
- LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, MONTEFIORE
- Study
- CALGB-40503
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: